Merck Sharpe & Dohme and Genentech have filed a Joint Motion to Terminate IPR2016-00710, relating to U.S. Patent No. 6,331,415.  As we reported earlier, the ‘415 patent is known as one of the “Cabilly” patents, and is generally applicable to manufacturing recombinant antibodies.  According to the motion, the parties have reached a settlement agreement concerning the ‘415 patent.